Acquisition and Long-term Carriage of Multidrug-Resistant Organisms in US International Travelers

Colin J. Worby,1,2 Ashley M. Earl,3 Sarah E. Turbett,1,4 Margaret Becker,4 Sowmya R. Rao,1,4 Elizabeth Oliver,1 Allison Taylor Walker,1 Maroyna Walters,1 Paul Kelly,1 Daniel T. Leung,1,4 Mark Knouse,1,4 Stefan H. F. Hagmann,1,2,4 Edward T. Ryan,1,5,6 and Regina C. LaRocque5,6

1Infectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; 2Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA; 3Harvard Medical School, Boston, Massachusetts, USA; 4Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA; 5Biostatistics Center, Massachusetts General Hospital, Boston, Massachusetts, USA; 6Department of Global Health, Boston University School of Public Health, Boston, Massachusetts, USA, 7Division of Global Migration and Quarantine, Travelers’ Health Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA, 8Division of Healthcare Quality Promotion, Prevention and Response Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA, 9Bronx Care Center, New York, New York, USA, 10University of Utah, Salt Lake City, Utah, USA, 11Lehigh Valley Medical Center, Allentown, Pennsylvania, USA, 12Cohen Children’s Medical Center, New Hyde Park, New York, USA, and 13Department of Immunology and Infectious Diseases, Harvard TH Chan School of Public Health, Boston, Massachusetts, USA.

We performed prospective screening of stool for multidrug-resistant organisms from 608 US international travelers and identified an acquisition rate of 38% following travel. Carriage rates remained significantly elevated for at least 6 months post-travel. Travel-related diarrhea was a risk factor for acquisition, as well as for long-term carriage upon return.

Keywords. antibiotic resistance; CRE; ESBL; mcr; travelers’ health.

Infections caused by multidrug-resistant organisms (MDROs) are a major cause of morbidity and mortality, and the burden continues to increase. The global dissemination of novel resistance mechanisms can be rapid and is facilitated in part by international travel. Many regions are known to be “hotspots” of high MDRO prevalence [1], a phenomenon that may relate to widespread antibiotic use in health care and agriculture [2]. Acquisition of extended-spectrum beta-lactamase-producing Enterobacteriales (ESBL-PE) is particularly common among travelers visiting South and Southeast Asia [3–5]. Recent work has also highlighted the risk of acquiring other MDROs of major public health concern during travel, including mcr-mediated colistin-resistant Enterobacteriales (mcr-E) and carbapenemase-producing carbapenem-resistant Enterobacteriales (CP-CRE) [6, 7].

In addition to the individual-level risk of acquisition, introduction and spread of travel-acquired MDROs may play a role in domestic transmission and outbreaks of these organisms. Household transmission of travel-acquired MDROs is known to occur [3], and prolonged carriage will increase the risk of such community spread. The few studies that have evaluated the duration of MDRO carriage by international travelers indicate that some can remain colonized for up to a year [3, 4]. Understanding the frequency of MDRO acquisition among travelers and the risk factors associated with persistent MDRO colonization can inform strategies for combatting their importation and spread. Here, we present data from a large, ongoing, prospective study of US international travelers, in which subjects were followed for up to a year post-travel to explore factors linked to acquisition and long-term carriage of MDROs. In addition to screening for ESBL-PE, this is the first large study to investigate acquisition and carriage of mcr-E and CP-CRE among travelers.

Participants were recruited from 5 US travel clinics (Table 1) at a pretravel health encounter. A total of 608 travelers (including 19 children; age range, 1–85 years) were enrolled and provided stool samples before travel (median [interquartile range {IQR}], 5 [2–7] days) and upon return (median [IQR], 11 [7–16] days post-travel). Samples were screened for ESBL-PE, mcr-E, and CP-CRE using culture-based protocols followed by phenotypic (ESBL-PE, CP-CRE) or molecular (mcr-E) confirmatory testing as defined by the Clinical Laboratory Standards Institute (CLSI) and Centers for Disease Control and Prevention [8–10]; a traveler was considered colonized with an MDRO if 1 or more of these Enterobacteriales organisms were detected. Travelers carrying MDROs upon return provided additional stool samples at 3, 6, and 12 months post-travel. Risk factors for pretravel carriage were assessed using a 2-sided Fisher exact test (binary variables) or a Wilcoxon rank-sum test (continuous variables). Risk factors for acquisition and carriage at subsequent sampling points were assessed similarly, excluding travelers who were colonized pretravel. Logistic regression models were fitted to explore multivariable relationships, and Cox proportional hazards models were used to estimate hazard ratios (HRs) for loss of carriage post-travel.

A total of 40 (6.6%) travelers carried MDROs before travel; all of these samples were positive for ESBL-PE, while 1 was additionally positive for mcr-E. Pretravel carriage was not associated with any reported underlying medical condition, nor with recent international travel (Table 1). Bronx Care enrollees had a significantly higher pretravel carriage rate (15%).
Table 1. Traveler Characteristics and Risk Factors for Pretravel Carriage and Acquisition of Multidrug-Resistant Organisms

|                                      | Pretravel (n = 608) | MDRO Acquisition During Travel (n = 568) |
|--------------------------------------|---------------------|----------------------------------------|
|                                      | No. | Positive | Negative | OR  | 95% CI | P   | No. | Yes | No | OR  | 95% CI | P   |
| Age, mean, y                         | 54.6 | 49.2     | —        | —   | .07    |     | 49.4 | 49.1 | —   | —   | .07    |     |
| Gender (female)                      | 372  | 26 (7%)  | 346 (93%)| —   | .07    |     | 346  | 122 (35%)| 224 (65%)| 0.73 | 0.51 | 1.04 .08 |
| Underlying medical conditions        | 450  | 31 (7%)  | 419 (93%)| 1.19 | 0.58 | 2.52 .73 | 419  | 154 (37%)| 265 (63%)| 0.79 | 0.53 | 1.19 .24 |
| Enrollment site                     | —    |          |          | —   | .07    |     | 353  | 127 (36%)| 226 (64%)| —   | —   | .07    |     |
| MGH, Boston, MA                     | 373  | 20 (5%)  | 353 (95%)| —   | .07    |     | 353  | 127 (36%)| 226 (64%)| —   | —   | .07    |     |
| Bronx Care, New York, NY^a          | 81   | 12 (15%)| 69 (85%) | 3.06 | 1.30 | 6.93 .01 | 69   | 38 (55%)| 31 (45%) | 2.18 | 1.26 | 3.81 .004 |
| University of Utah Hospital, Salt Lake City, UT^a | 58   | 2 (3%)  | 56 (97%) | 0.63 | 0.07 | 2.72 .75 | 56   | 28 (50%)| 28 (50%) | 1.78 | 0.97 | 3.27 .05 |
| Northwell Health, New York, NY^a     | 34   | 2 (6%)  | 32 (94%) | 0.63 | 0.07 | 2.72 .75 | 34   | 2 (6%)  | 32 (94%) | 0.63 | 0.07 | 2.72 .75 |
| Lehigh Valley Medical Center, PA^a   | 62   | 4 (6%)  | 58 (94%) | 0.63 | 0.07 | 2.72 .75 | 62   | 4 (6%)  | 58 (94%) | 0.63 | 0.07 | 2.72 .75 |
| In the year before enrollment:      |      |          |          |      | .07    |     |      |      |      |      | .07    |     |
| International travel                | 302  | 19 (6%)  | 283 (94%)| 0.73 | 0.35 | 1.57 .38 | 283  | 103 (36%)| 180 (64%)| 0.84 | 0.56 | 1.26 .37 |
| Antibiotic use                      | 156  | 11 (7%)  | 145 (93%)| 0.99 | 0.42 | 2.16 1.00 | 145  | 50 (34%)| 95 (66%) | 0.81 | 0.52 | 1.24 .35 |
| Hospitalization                     | 35   | 2 (6%)  | 33 (94%) | 0.80 | 0.09 | 3.38 1.00 | 33   | 7 (21%) | 26 (79%) | 0.42 | 0.15 | 1.02 .04 |
| Regularly taking:                   |      |          |          |      | .07    |     |      |      |      |      | .07    |     |
| Proton pump inhibitor/H2 blocker    | 75   | 6 (8%)  | 69 (92%) | 1.28 | 0.42 | 3.23 0.62 | 69   | 25 (36%)| 44 (64%) | 0.91 | 0.52 | 1.57 .79 |
| Bismuth                             | 7    | 0 (0%)  | 7 (100%) | 0.00 | 0.00 | 10.10 1.00 | 7    | 4 (57%) | 3 (43%) | 2.18 | 0.36 | 15.00 .44 |
| Other antacid                       | 42   | 2 (5%)  | 40 (95%) | 0.70 | 0.08 | 2.87 1.00 | 40   | 17 (43%)| 23 (58%) | 1.21 | 0.59 | 2.44 .61 |
| During travel:                      |      |          |          |      | .07    |     |      |      |      |      | .07    |     |
| Travel duration, median, d          | 14   | 13       | —        | —   | .07    |     | 14   | 13       | —       | —   | .07    |     |
| VFR                                 | 39   | 23 (60%)| 16 (41%) | 2.48 | 1.22 | 5.16 .01 | 24   | 12 (50%)| 12 (50%) | 1.00 | 0.53 | 2.00 .004 |
| Leisure                             | 407  | 144 (35%)| 263 (65%)| 0.66 | 0.44 | 0.97 .03 | 24   | 12 (50%)| 12 (50%) | 1.00 | 0.53 | 2.00 .004 |
| Business                            | 59   | 24 (41%)| 35 (59%) | 1.12 | 0.62 | 2.01 .67 | 24   | 12 (50%)| 12 (50%) | 1.00 | 0.53 | 2.00 .004 |
| Street food                         | 155  | 66 (43%)| 89 (57%) | 1.29 | 0.87 | 1.90 2.1 |
| Undercooked meat                    | 45   | 10 (22%)| 35 (78%) | 0.44 | 0.19 | 0.93 .02 | 24   | 12 (50%)| 12 (50%) | 1.00 | 0.53 | 2.00 .004 |
| Unfiltered tap water                | 122  | 47 (39%)| 75 (61%) | 1.02 | 0.66 | 1.56 .1 |
| Unwashed fruit                      | 285  | 101 (35%)| 184 (65%)| 0.79 | 0.65 | 1.13 .2 |
| Uncooked vegetables                 | 291  | 113 (39%)| 178 (61%)| 1.06 | 0.74 | 1.50 .8 |
| Dined in family home                | 202  | 86 (43%)| 116 (57%)| 1.33 | 0.92 | 1.92 .13 | 24   | 12 (50%)| 12 (50%) | 1.00 | 0.53 | 2.00 .004 |
| Diarrhea                            | 185  | 89 (48%)| 96 (52%) | 1.87 | 1.29 | 2.74 <.001 |
| Malaria                             | 274  | 105 (38%)| 169 (62%)| 1.01 | 0.71 | 1.44 .1 |
| Doxycycline                         | 6    | 3 (50%) | 3 (50%) | 1.62 | 0.22 | 12.25 .68 |
| Any antibiotics                     | 82   | 43 (52%)| 39 (48%) | 2.00 | 1.21 | 3.30 .004 |

For binary outcomes, a 2-sided Fisher exact test was applied; continuous variables were compared using the Wilcoxon rank-sum test. Variance across enrollment sites was assessed using a chi-square test; this was not performed for baseline carriage rates due to low numbers.

Abbreviations: MGH, Massachusetts General Hospital; OR, odds ratio; VFR, returning to region of origin of self or family to a low- or low-middle-income country to visit friends and relatives.

^aIndividual enrollment sites were compared with MGH using a 2-sided Fisher exact test. Missing responses are excluded from analyses.
Of the 568 travelers testing negative for MDROs pretravel, 217 (38%) had at least 1 MDRO detected upon return (97% of which were Escherichia coli), suggesting travel-associated acquisition. The highest rates of MDRO acquisition were among travelers to South Asia (39/66; 59%) and Southeast Asia (34/72; 47%) (Figure 1A). Trip duration was not associated with risk of acquisition (Table 1). Acquisition of ESBL-PE (212 travelers; 37%) was more common than acquisition of mcr-E (28 travelers; 4.9%) or CP-CRE (2 travelers; 0.4%). Among 28 travelers acquiring mcr-E, 24 (86%) also acquired ESBL-PE. Despite having the highest overall acquisition rates, South Asia was not associated with any mcr-E acquisition; this was most common during travel to South America (11%) and Southeast Asia (12%) (Figure 1A). Only 2 travelers acquired CP-CRE; these travelers visited South and Southeast Asia.

Of the evaluated dietary and behavioral factors, only consumption of undercooked or raw meat was associated with decreased risk (Figure 1C, Table 1). This was correlated with travel to low-risk regions (East Asia and Southern Africa) and was no longer a significant risk factor after adjusting for travel destination. Acquisition rates also differed by enrollment site (Table 1); this could be explained by differential travel...
locations between sites, with travel to Western Africa being much more frequent among Bronx Care enrollees (48%) than others (6%). Diarrhea (3 or more episodes of loose stool in a 24-hour period) and antibiotic use were independently associated with acquisition of MDROs (Figure 1C). Many travelers experiencing diarrhea took antibiotics to treat symptoms (46/193; 24%), most commonly azithromycin (24/193; 12%) and ciprofloxacin (17/193; 9%). Among travelers with diarrhea, those who took antibiotics to treat symptoms were more likely to acquire MDROs than those who did not (65% vs 40%; \( P = .004 \)); travelers taking ciprofloxacin had a particularly high MDRO acquisition rate (13/17; 76%). Diarrhea remained significantly associated with MDRO acquisition (odds ratio [OR], 1.11; 95% CI, 1.02–1.21; \( P = .01 \)) after adjusting for travel destination, trip duration, and antibiotic use during travel.

Among travelers who acquired MDROs, 33% were colonized 3 months after returning and 17% at 6 months, significantly higher than pretravel colonization prevalence among all travelers (\( P < .001 \)). At 12 months, 10% of those with acquired MDROs were still colonized, comparable to pretravel rates (Figure 1B). Relatively few mcr-E and CP-CRE were acquired, limiting our power to estimate long-term carriage of these specific organisms; however, 4/25 (16%) travelers acquiring mcr-E were colonized at 3 months, which was significantly higher than observed pretravel (0.2%; \( P < .001 \)). Neither of the 2 travelers who acquired CP-CRE was colonized at 3 months. No clinical infections or hospitalizations were reported during the study follow-up.

Carriage rates varied slightly by travel destination, potentially suggesting geographic heterogeneity of acquired phenotypes. At 3 months, MDRO carriage rates ranged from 14% in travelers who visited Western Africa to 46% in travelers visiting Southeast Asia. Travelers experiencing diarrhea during their trip were more likely to acquire MDROs and were more likely to remain colonized during the follow-up period (Figure 1D). Among travelers who acquired MDROs, at 6 months post-travel, 24% of those who experienced travelers’ diarrhea remained colonized with an MDRO, which was significantly higher than the 11% of those who did not report diarrhea (\( P = .04 \)). Diarrhea remained a significant risk factor for travel-acquired MDRO carriage at 6 months (OR, 1.14; 95% CI, 1.01–1.29; \( P = .03 \)) after adjusting for travel destination and duration. Diarrhea during travel, whether treated with antibiotics or not, was associated with elevated risk of post-travel carriage (HR of carriage loss for treated diarrhea, 0.54; 95% CI, 0.33–0.89; \( P = .02 \); HR for untreated diarrhea, 0.68; 95% CI, 0.46–0.99; \( P = .04 \); multivariable Cox proportional hazards model). The additional risk associated with antibiotic use was not significant (\( P = .2 \)).

Subsequent international travel was reported by 18 (10%), 25 (17%), and 15 (17%) travelers with acquired MDROs at the 3-, 6-, and 12-month follow-up time points, respectively. This was a significant risk factor for carriage of MDROs during the follow-up period, though even after excluding these travelers, carriage remained significantly higher than pretravel levels at 3 months (33%) and 6 months (19%) post-travel. In a multivariable Cox proportional hazards model, subsequent travel (HR, 0.1; 95% CI, 0.03–0.3; \( P = .0001 \)) and travelers’ diarrhea (HR, 0.7; 95% CI, 0.5–0.98; \( P = .038 \)) were both significantly associated with ongoing carriage (Figure 1D).

Subsequent antibiotic use, reported by 57 travelers who acquired MDROs, had no significant effect on carriage duration (HR, 1.02; 95% CI, 0.72–1.44).

This is the first large prospective study of MDRO carriage and acquisition in US international travelers. Acquisition rates were consistent with previous European studies [3, 4] that focused on ESBL-PE acquisition. Acquisition and importation of bacteria with mcr-mediated resistance to colistin, an antibiotic of last resort, is concerning, particularly as many travel-acquired mcr-E are also ESBL-producing [6], leaving limited therapeutic options for infections with these organisms. Further dissemination via horizontal gene transfer is an additional concern for such mobilized resistance mechanisms. Notably, while travel to South and Southeast Asia is known to be associated with elevated risks of MDRO acquisition, we found South America to have one of the highest rates of mcr-E acquisition among our traveler cohort. These travelers visited Peru (13/14 acquisitions) and Ecuador (1/14), mostly traveling for leisure (12/14). Limited studies on colistin resistance in South America suggest that mcr-E circulates in agricultural settings [11] and that commercial chicken meat may be a reservoir for mcr-E [12]. Peru banned the importation and manufacture of colistin only in late 2019 [13].

Diarrhea is known to be associated with MDRO acquisition while overseas [5], but our study suggests that it is also associated with prolonged colonization. We found that antibiotic use, particularly ciprofloxacin, was also associated with increased acquisition risk, and its use as a treatment for diarrhea contributed to enhanced risk of acquisition and long-term carriage of MDROs. Diarrhea and antibiotic treatment are known to disrupt the gut microbiome, which can facilitate the colonization and persistence of MDROs [14]. Further studies are needed to determine the role of the gut microbiota in susceptibility to MDRO colonization in travelers.

We cannot ensure that MDROs detected at later time points are the same strains acquired during travel. However, carriage rates among participants with no subsequent travel remain significantly elevated after 6 months, which supports our hypothesis that MDROs acquired during travel can lead to long-term colonization. Furthermore, our observations of long-term posttravel carriage are consistent with a previous study of Dutch travelers, in which 17% of participants acquiring ESBL-PE during travel remained colonized after 6 months [4]. Future genomic sequencing efforts of travel-acquired MDROs will enable
longitudinal strain tracking and identification of genetic factors linked to gut persistence.

**Acknowledgments**

**Financial support.** This work was supported by grants (U19CI000514, U01CK000175, and U01CK000490) from the Centers for Disease Control and Prevention.

**Potential conflicts of interest.** The authors declare no conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

**Patient consent.** Written consent was obtained from all participants in the study. Institutional review board approval was obtained from the human research committee at each participating enrollment site.

**References**

1. Woerther PL, Burdet C, Chachaty E, Andremont A. Trends in human fecal carriage of extended-spectrum β-lactamases in the community: toward the globalization of CTX-M. Clin Microbiol Rev 2013; 26:744–58.
2. Chokshi A, Sifri Z, Cennimo D, Horng H. Global contributors to antibiotic resistance. J Glob Infect Dis 2019; 11:36–42.
3. Arcilla MS, van Hattem JM, Haverkate MR, et al. Import and spread of extended-spectrum β-lactamase-producing Enterobacteriaceae by international travellers (COMBAT study): a prospective, multicentre cohort study. Lancet Infect Dis 2017; 17:78–85.
4. Paltansing S, Vlot JA, Kraaikman ME, et al. Extended-spectrum β-lactamase-producing enterobacteriaceae among travelers from the Netherlands. Emerg Infect Dis 2013; 19:1206–13.
5. Woerther PL, Andremont A, Kantele A. Travel-acquired ESBL-producing Enterobacteriaceae: impact of colonization at individual and community level. J Travel Med 2017; 24:29–34.
6. Mellon G, Turbett SE, Worby C, et al. Acquisition of antibiotic-resistant bacteria by U.S. international travelers. N Engl J Med 2020; 382:1372–4.
7. Schaumburg F, Sertic SM, Correa-Martinez C, et al. Acquisition and colonization dynamics of antimicrobial-resistant bacteria during international travel: a prospective cohort study. Clin Microbiol Infect 2019; 25:1287 e1–7.
8. Turbett SE, Desrosiers L, Andrews-Dunleavey C, et al. Evaluation of a screening method for the detection of colistin-resistant enterobacteriaceae in stool. Open Forum Infect Dis 2019; 6:XXX–XX.
9. Turbett SE, Becker M, Desrosiers L, et al. The effect of transport temperature and time on the recovery of antimicrobial resistant Enterobacterales in stool. Diagn Microbiol Infect Dis 2020; 99:115210.
10. CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 27th ed. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2017.
11. Fernandes MR, Moura Q, Sartori L, et al. Silent dissemination of colistin-resistant *Escherichia coli* in South America could contribute to the global spread of the mcr-1 gene. Euro Surveill 2016; 21. doi:10.2807/1560-7917.ES.2016.21.17.30214
12. Monte DF, Mem A, Fernandes MR, et al. Chicken meat as a reservoir of colistin-resistant *Escherichia coli* strains carrying mcr-1 genes in South America. Antimicrob Agents Chemother 2017; 61:e02718–16.
13. Ministerio de Agricultura y Riego Minagri: prohiben importación, comercialización y fabricación de colistina en el país. Available at: https://www.gob.pe/institucion/minagri/noticias/70129-minagri-prohiben-importacion-comercializacion-y-fabricacion-de-colistina-en-el-pais. Accessed 25 April 2020.
14. Khosravi A, Mazmanian SK. Disruption of the gut microbiome as a risk factor for microbial infections. Curr Opin Microbiol 2013; 16:221–7.